SUNNYVALE, Calif., June 17, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today the company has
launched the CyberKnife® S7™ System, an innovative
device combining speed, advanced precision, and real-time
artificial intelligence (AI)-driven motion tracking and
synchronization treatment delivery for all stereotactic
radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
treatments — in as little as 15 minutes. The CyberKnife S7 System
is the next-generation CyberKnife platform, a robotic, non-invasive
radiation therapy device capable of treating cancerous and benign
tumors throughout the body, as well as neurologic disorders. The
new CyberKnife technology is the most recent illustration of
Accuray innovation in radiation therapy that empowers healthcare
providers through new capabilities to provide the best possible
care to their patients.
Many changes can happen during treatment: the patient shifts
position, breathes, or coughs, muscles tense and relax, fluids and
gasses displace internal organs. This movement can impact the
location of the tumor target when the radiation beam is delivered.
The CyberKnife System's Synchrony® motion
synchronization technology uses AI to adapt radiation delivery in
real-time to patient and/or tumor movement throughout the course of
treatment. The system's robotic design facilitates the delivery of
radiation from potentially thousands of unique angles,
significantly expanding the possible positions from which radiation
beams can be delivered. The more angles and points in space from
which to approach the tumor, the better a physician will be able to
maximize radiation dose delivered to the tumor and minimize dose to
surrounding healthy tissues. The CyberKnife System is the only
device capable of delivering sub-millimetric stereotactic
treatments anywhere in the body with speed, efficiency and accuracy
— all without the need for human intervention.
"Geisinger is dedicated to making exceptional cancer care
available to residents of northeastern Pennsylvania, within their community," said
chairman of radiation oncology at Geisinger Cancer Institute, Dr.
Anand Mahadevan. "We are proud to be
the first center in the world to treat patients with the CyberKnife
S7 System, an advanced device that will expand the scope of tumors
we can treat. Knowing that the system will automatically adapt
treatment delivery for patient or tumor movement gives us the
confidence to use SRS and SBRT for intra- and extra-cranial disease
sites throughout the body, providing meaningful benefits to our
patients during and after treatment."
Learn more about the CyberKnife S7 System here.
The CyberKnife S7 is built for the speed clinicians need for
operational efficiency. Accurate, sub-millimetric, motion
synchronized, (ultra) hypofractionated treatments can be delivered
in as little as 15 minutes with Synchrony and the VOLO™ Optimizer,
providing the patient throughput necessary to be successful in
today's clinical environment. SRS and SBRT use advanced techniques
to deliver precise, hypofractionated radiation therapy — which
allows patients to be treated with very high doses of accurately
targeted radiation administered in a few days versus conventional
fractionation where treatments often require up to 35 visits.
Patient benefits can include a shorter overall course of treatment
and a significant reduction in the risk of side effects that can
significantly impact patients' lives.
Changes to the proposed Medicare & Medicaid Radiation
Oncology – Alternative Payment Model favor the delivery of
hypofractionated radiotherapy whenever clinically appropriate.
Radiotherapy devices like the CyberKnife platform provide a
resource for hospitals to achieve both their clinical efficacy and
ROI goals.
"We are gratified to have achieved this important CyberKnife
System milestone with the support from Dr. Mahadevan and his team.
The CyberKnife system has continued to evolve since the first
patient was treated more than 25 years ago and it remains the 'go
to' device for clinicians who want to confidently deliver precise
and accurate stereotactic treatments on a day-in, day-out basis,"
said Joshua H. Levine, president and
CEO at Accuray. "With the introduction of the CyberKnife S7 System,
Accuray is continuing its legacy of innovation. We believe this new
system will make it easier for Geisinger clinicians to successfully
deliver SRS and SBRT and achieve their patient-first treatment
objectives, a priority for their team and ours."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications and
clinical results. These forward-looking statements involve risks
and uncertainties. If any of these risks or uncertainties
materialize, or if any of the company's assumptions prove
incorrect, actual results could differ materially from the results
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products; the company's ability to develop new products or improve
existing products to meet customers' needs; the company's ability
to anticipate or keep pace with changes in the marketplace and the
direction of technological innovation and customer demands and such
other risks identified under the heading "Risk Factors" in the
company's quarterly report on Form 10-Q, filed with the Securities
and Exchange Commission (the "SEC") on May
8, 2020, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-launches-new-cyberknife-s7-system-301078359.html
SOURCE Accuray Incorporated